NBTX Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Nanobiotix SA's net margin of --. Nanobiotix SA's return on equity of -- beat DBV Technologies SA's return on equity of -280.59%.

Nanobiotix SA has a consensus price target of $19.14, signalling downside risk potential of -6.83%. On the other hand DBV Technologies SA has an analysts' consensus of $39.69 which suggests that it could grow by 133.35%. Given that DBV Technologies SA has higher upside potential than Nanobiotix SA, analysts believe DBV Technologies SA is more attractive than Nanobiotix SA.

Nanobiotix SA has a beta of 0.704, which suggesting that the stock is 29.588% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.166, suggesting its less volatile than the S&P 500 by 216.581%.

Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Nanobiotix SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Nanobiotix SA's net income of -- is lower than DBV Technologies SA's net income of -$33M. Notably, Nanobiotix SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 28.65x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Innate Pharma SA has a net margin of -- compared to Nanobiotix SA's net margin of --. Nanobiotix SA's return on equity of -- beat Innate Pharma SA's return on equity of -72.79%.

Nanobiotix SA has a consensus price target of $19.14, signalling downside risk potential of -6.83%. On the other hand Innate Pharma SA has an analysts' consensus of $5.15 which suggests that it could grow by 192.84%. Given that Innate Pharma SA has higher upside potential than Nanobiotix SA, analysts believe Innate Pharma SA is more attractive than Nanobiotix SA.

Nanobiotix SA has a beta of 0.704, which suggesting that the stock is 29.588% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of -0.018, suggesting its less volatile than the S&P 500 by 101.755%.

Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend.

Nanobiotix SA quarterly revenues are --, which are smaller than Innate Pharma SA quarterly revenues of --. Nanobiotix SA's net income of -- is lower than Innate Pharma SA's net income of --. Notably, Nanobiotix SA's price-to-earnings ratio is -- while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 28.65x versus 22.73x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

Inventiva SA has a net margin of -- compared to Nanobiotix SA's net margin of --. Nanobiotix SA's return on equity of -- beat Inventiva SA's return on equity of --.

Nanobiotix SA has a consensus price target of $19.14, signalling downside risk potential of -6.83%. On the other hand Inventiva SA has an analysts' consensus of $15.00 which suggests that it could grow by 210.57%. Given that Inventiva SA has higher upside potential than Nanobiotix SA, analysts believe Inventiva SA is more attractive than Nanobiotix SA.

Nanobiotix SA has a beta of 0.704, which suggesting that the stock is 29.588% less volatile than S&P 500. In comparison Inventiva SA has a beta of 0.708, suggesting its less volatile than the S&P 500 by 29.184%.

Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend.

Nanobiotix SA quarterly revenues are --, which are smaller than Inventiva SA quarterly revenues of --. Nanobiotix SA's net income of -- is lower than Inventiva SA's net income of --. Notably, Nanobiotix SA's price-to-earnings ratio is -- while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 28.65x versus 28.12x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.

Valneva SE has a net margin of -- compared to Nanobiotix SA's net margin of -150.82%. Nanobiotix SA's return on equity of -- beat Valneva SE's return on equity of -56.21%.

Nanobiotix SA has a consensus price target of $19.14, signalling downside risk potential of -6.83%. On the other hand Valneva SE has an analysts' consensus of $11.51 which suggests that it could grow by 32.18%. Given that Valneva SE has higher upside potential than Nanobiotix SA, analysts believe Valneva SE is more attractive than Nanobiotix SA.

Nanobiotix SA has a beta of 0.704, which suggesting that the stock is 29.588% less volatile than S&P 500. In comparison Valneva SE has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Valneva SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. Valneva SE pays out -- of its earnings as a dividend.

Nanobiotix SA quarterly revenues are --, which are smaller than Valneva SE quarterly revenues of $34.4M. Nanobiotix SA's net income of -- is lower than Valneva SE's net income of -$51.8M. Notably, Nanobiotix SA's price-to-earnings ratio is -- while Valneva SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 28.65x versus 4.07x for Valneva SE. Usually stocks with elevated PS ratios are considered overvalued.